Association Between Asymmetric Dimethylarginine, Its Change, and Subclinical Carotid Atherosclerosis in Metabolic Dysfunction–Associated Steatotic Liver Disease
Journal of Digestive Diseases · 2026-01 · 27 (1-2) · 75-86
DOI: 10.1111/1751-2980.70045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Digestive Diseases, online erschienen am 01.04.2026. Verfasst von Wei Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Arginine, Carotid Artery Diseases, Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit nennt 21 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Friendship Hospital, Capital Medical University.
Abstract (Originalsprache)
Objective
To examine whether baseline levels and short‐term changes of asymmetric dimethylarginine (ADMA) are associated with subclinical carotid atherosclerosis (SCA) and its progression in adults with metabolic dysfunction–associated steatotic liver disease (MASLD).
Methods
A total of 600 adults with MASLD were prospectively recruited and followed annually for 2 years. Serum ADMA was measured at baseline and 1‐year follow‐up. SCA, defined as increased carotid intima‐media thickness or carotid plaque, was assessed at baseline, 1‐ and 2‐year follow‐up. Multivariable regression and propensity score‐based analyses were performed to assess the associations between baseline ADMA or change in ADMA and SCA risk.
Results
Increased baseline ADMA level was significantly associated with SCA. Each 1‐standard deviation (SD) increase in baseline ADMA was associated with higher odds of SCA (odds ratio 2.24, 95% confidence interval [CI] 1.66–3.01), with a dose–response relationship across ADMA quartiles. Baseline ADMA was not associated with SCA progression; however, dynamic increase in ADMA over time was strongly associated with SCA progression at both 1 and 2 years. Each 1‐SD increase in absolute and relative changes of ADMA was associated with higher risks of SCA progression at 1 year (relative risk [RR] 1.82, 95% CI 1.60–2.07; RR 1.44, 95% CI 1.29–1.61) and 2 years (RR 1.52, 95% CI 1.36–1.70; RR 1.31, 95% CI 1.20–1.42). Associations were more pronounced among participants with pre‐existing SCA.
Conclusion
ADMA is associated with the prevalence of SCA, and short‐term dynamic changes in ADMA may represent early indicators for SCA progression in adults with MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Clinical Epidemiology and EBM Unit, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Ultrasound, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Peng Fei Sun, Min Li
Förderung
- National Natural Science Foundation of China
- Beijing Friendship Hospital, Capital Medical University
Zitieren
APA
Wang, W., Ren, X. T., Sun, P. F., Lyu, T. T., Wang, Y., Tan, Y. F., Zhao, X. Y., & Li, M. (2026). Association Between Asymmetric Dimethylarginine, Its Change, and Subclinical Carotid Atherosclerosis in Metabolic Dysfunction–Associated Steatotic Liver Disease. Journal of Digestive Diseases, 27(1-2), 75-86. https://doi.org/10.1111/1751-2980.70045
Vancouver
Wang W, Ren XT, Sun PF, Lyu TT, Wang Y, Tan YF, et al. Association Between Asymmetric Dimethylarginine, Its Change, and Subclinical Carotid Atherosclerosis in Metabolic Dysfunction–Associated Steatotic Liver Disease. Journal of Digestive Diseases. 2026;27(1-2):75-86. doi:10.1111/1751-2980.70045
BibTeX
@article{Wang2026,
author = {Wang, Wei and Ren, Xin Tian and Sun, Peng Fei and Lyu, Ting Ting and Wang, Yu and Tan, Yan Fang and Zhao, Xin Yan and Li, Min},
title = {Association Between Asymmetric Dimethylarginine, Its Change, and Subclinical Carotid Atherosclerosis in Metabolic Dysfunction–Associated Steatotic Liver Disease},
journal = {Journal of Digestive Diseases},
year = {2026},
volume = {27},
number = {1-2},
pages = {75--86},
doi = {10.1111/1751-2980.70045}
}
EUVIMED